Global Finance News
15 May 2026, 12:11
Celcuity Barely Moves as Phase 3 Win Already Priced In and Investors Await ASCO Data
May 14, 2026 | NASDAQ: CELC
Celcuity is essentially flat in premarket, down just 0.21%, in a reaction that reflects a stock where the most important catalyst — positive Phase 3 VIKTORIA-1 results — had already been disclosed and partially priced in before today's financial release. With the detailed data not arriving until ASCO on June 2, the market is in a holding pattern.
The clinical news is genuinely significant. VIKTORIA-1 achieved its primary endpoint in the PIK3CA mutant cohort, with gedatolisib in combination with fulvestrant and palbociclib demonstrating a statistically significant and clinically meaningful improvement in progression-free survival versus alpelisib plus fulvestrant — the current standard of care. Importantly, the gedatolisib doublet also beat alpelisib on the secondary endpoint. Both regimens showed manageable safety profiles with no new signals. A late-breaking oral presentation at ASCO on June 2 will be the next major catalyst, followed by an sNDA submission to the FDA in Q3 targeting a potential approval around the July 17 PDUFA date already assigned for the PIK3CA wild-type indication.
The VIKTORIA-2 expansion is also strategically important. The addition of Study 2 — evaluating gedatolisib plus palbociclib plus letrozole in approximately 740 treatment-naive endocrine-sensitive patients — opens the door to first-line positioning across nearly all HR+/HER2- advanced breast cancer patients regardless of PIK3CA status or endocrine sensitivity. The addressable population of approximately 60,000 newly diagnosed US patients annually with endocrine-sensitive disease is a meaningful commercial expansion of the original target.
On the financial side, net loss widened to $52.8 million from $37 million a year ago, with SG&A jumping from $6.3 million to $17.4 million as commercial launch preparations accelerate ahead of the anticipated Q3 approval. Cash of $387.1 million, combined with the debt facility, is guided to finance operations through 2027. The burn is intentional and appropriate — this is a company spending to be ready for launch.
The flat premarket reaction is simply a function of timing. June 2 at ASCO is the next true catalyst, and the FDA decision in July is the one that will define the year. Today's release is a financial housekeeping report for a company whose story is entirely clinical.
May 14, 2026 | NASDAQ: CELC
Celcuity is essentially flat in premarket, down just 0.21%, in a reaction that reflects a stock where the most important catalyst — positive Phase 3 VIKTORIA-1 results — had already been disclosed and partially priced in before today's financial release. With the detailed data not arriving until ASCO on June 2, the market is in a holding pattern.
The clinical news is genuinely significant. VIKTORIA-1 achieved its primary endpoint in the PIK3CA mutant cohort, with gedatolisib in combination with fulvestrant and palbociclib demonstrating a statistically significant and clinically meaningful improvement in progression-free survival versus alpelisib plus fulvestrant — the current standard of care. Importantly, the gedatolisib doublet also beat alpelisib on the secondary endpoint. Both regimens showed manageable safety profiles with no new signals. A late-breaking oral presentation at ASCO on June 2 will be the next major catalyst, followed by an sNDA submission to the FDA in Q3 targeting a potential approval around the July 17 PDUFA date already assigned for the PIK3CA wild-type indication.
The VIKTORIA-2 expansion is also strategically important. The addition of Study 2 — evaluating gedatolisib plus palbociclib plus letrozole in approximately 740 treatment-naive endocrine-sensitive patients — opens the door to first-line positioning across nearly all HR+/HER2- advanced breast cancer patients regardless of PIK3CA status or endocrine sensitivity. The addressable population of approximately 60,000 newly diagnosed US patients annually with endocrine-sensitive disease is a meaningful commercial expansion of the original target.
On the financial side, net loss widened to $52.8 million from $37 million a year ago, with SG&A jumping from $6.3 million to $17.4 million as commercial launch preparations accelerate ahead of the anticipated Q3 approval. Cash of $387.1 million, combined with the debt facility, is guided to finance operations through 2027. The burn is intentional and appropriate — this is a company spending to be ready for launch.
The flat premarket reaction is simply a function of timing. June 2 at ASCO is the next true catalyst, and the FDA decision in July is the one that will define the year. Today's release is a financial housekeeping report for a company whose story is entirely clinical.